Abstract
Although the selective serotonin reuptake inhibitors have become the first line medications for the treatment of depression, drugs primarily targeting the norepinephrine (NE) and/or the dopamine catecholaminergic systems are also effective. These include selective NE reuptake inhibitors, such as desipramine and reboxetine, the NE releaser bupropion and the α2-adrenergic antagonists mianserin and mirtazapine. Dopamine type 2 agonists are also effective in treating depression, although they are rarely used. Since the NE, dopamine and serotonin systems have reciprocal interactions, it is virtually impossible to act on a specific neuronal element without affecting in a cascade effect the two other systems. In this review, the primary actions of the catecholaminergic strategies upon their acute and long-term administration are described, as well as their impact on other systems. Their use in treatment-resistant depressed patients is also addressed.
Keywords: Dopamine, norepinephrine, serotonin, locus coeruleus, raphe nuclei, ventral tegmental area
Current Drug Targets
Title: Catecholaminergic Strategies for the Treatment of Major Depression
Volume: 7 Issue: 2
Author(s): Philippe Tremblay and Pierre Blier
Affiliation:
Keywords: Dopamine, norepinephrine, serotonin, locus coeruleus, raphe nuclei, ventral tegmental area
Abstract: Although the selective serotonin reuptake inhibitors have become the first line medications for the treatment of depression, drugs primarily targeting the norepinephrine (NE) and/or the dopamine catecholaminergic systems are also effective. These include selective NE reuptake inhibitors, such as desipramine and reboxetine, the NE releaser bupropion and the α2-adrenergic antagonists mianserin and mirtazapine. Dopamine type 2 agonists are also effective in treating depression, although they are rarely used. Since the NE, dopamine and serotonin systems have reciprocal interactions, it is virtually impossible to act on a specific neuronal element without affecting in a cascade effect the two other systems. In this review, the primary actions of the catecholaminergic strategies upon their acute and long-term administration are described, as well as their impact on other systems. Their use in treatment-resistant depressed patients is also addressed.
Export Options
About this article
Cite this article as:
Tremblay Philippe and Blier Pierre, Catecholaminergic Strategies for the Treatment of Major Depression, Current Drug Targets 2006; 7 (2) . https://dx.doi.org/10.2174/138945006775515464
DOI https://dx.doi.org/10.2174/138945006775515464 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Perspectives on Medicinal Properties of Benzoquinone Compounds
Mini-Reviews in Medicinal Chemistry Prognostic Role of miRNAs in Coronary Artery Disease
Current Topics in Medicinal Chemistry Neuropeptide - Adipose Tissue Communication and Intestinal Pathophysiology
Current Pharmaceutical Design The Tree of Sirtuins and the Garden of Cardiovascular Youth
Current Vascular Pharmacology Your Father and Grandfather’s Atrial Fibrillation: A Review of the Genetics of the Most Common Pathologic Cardiac Dysrhythmia
Current Genomics New Pharmacological Approaches in Infants with Hypoxic-Ischemic Encephalopathy
Current Pharmaceutical Design The Role of “Eye Platelet Rich Plasma” (E-Prp) for Wound Healing in Ophthalmology
Current Pharmaceutical Biotechnology Energetic Metabolic Roles in Pulmonary Arterial Hypertension and Right Ventricular Remodeling
Current Pharmaceutical Design Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis
Current Pharmaceutical Design The Chick Embryo Chorioallantoic Membrane as a Model for in vivo Research on Anti-Angiogenesis
Current Pharmaceutical Biotechnology Inflammatory Mechanisms and Redox Status in Periodontal and Cardiometabolic Diseases: Effects of Adjunctive Nutritional Antioxidants and Statins
Infectious Disorders - Drug Targets Nitric Oxide in the Dorsal Medulla Modulates Excitatory Somatosympathetic Reflexes
Current Cardiology Reviews Polymorphism in Endothelin-1 Gene: An Overview
Current Clinical Pharmacology Behavioral Effects of 2,3-Dihydro- and Oxoisoaporphine Derivatives in Post Stroke-Depressive Like Behavior in Male Balb/c Mice
Current Topics in Medicinal Chemistry Screening and Preponderance of Peptic Ulcer and its Contributing Risk Factors Among Basrah City Residents in Iraq
Current Drug Safety Calcium Sensitizers in Cardiac Surgery: Who, When, How and Why?
Current Vascular Pharmacology Membrane Rafts in the Respiratory System
Current Respiratory Medicine Reviews How to Investigate the Vascular Changes in Resistant Hypertension
Current Hypertension Reviews Coronary Microvascular and Cardiac Dysfunction Due to Homocysteine Pathometabolism; A Complex Therapeutic Design
Current Pharmaceutical Design Atrial Macroreentry in Congenital Heart Disease
Current Cardiology Reviews